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The commercial success of foods depends more and more on what science says about the 
effects of these foods on health. Drug 
companies have tried to inﬂ uence the 
scientiﬁ c record so as to make their 
products look healthier [1,2]; are food 
companies doing the same? In a study 
published in PLoS Medicine, Lesser et 
al. [3] investigated this by analyzing 
206 publications on the health effects 
of milk, soft drinks, and fruit juices. 
Twenty-four of these studies had been 
funded solely by the industry whose 
product was investigated, while 52 of 
the papers declared that they had had 
no industrial support. The other papers 
had mixed support or did not declare 
sponsorship. 
The odds that a paper would report 
a favorable outcome were four to 
eight times higher when the study 
was funded by the manufacturer of 
the beverages in question than when 
the study was not funded by industry. 
Out of the 35 interventional studies, 
which included human trials, industry 
was the sole sponsor of 16, and none 
of these 16 reported an unfavorable 
outcome. In contrast, seven of the 19 
interventional studies with mixed or no 
industry funding found an unfavorable 
effect. Thus, papers sponsored by 
industry were more likely to report 
favorable outcomes for that industry’s 
beverages than papers with other 
sources of funding.
The study by Lesser et al. was 
carefully done, the number of articles 
was sufﬁ ciently large, the analyses were 
straightforward, and they agree with 
the outcomes of earlier, smaller studies. 
However, an association between 
funding and outcome does not by itself 
prove bias. First, ﬁ ve of the papers 
dealt with outbreaks of food poisoning 
and none of these studies was funded 
by industry, which strengthened the 
correlation of unfavorable outcomes 
with the absence of industry funding. 
But industry was, of course, never asked 
to fund these studies and therefore 
bias was not an issue. Second, when 
producers plan to fund a nutrition 
study, they will naturally select a 
product with a potentially favorable 
nutritional proﬁ le.
However, such selection is the start 
of a slippery slope. When an industry 
is the major sponsor of research on 
its own product, unfavorable effects 
of that product are less likely to be 
investigated. The next step down the 
slope is adjustment of designs. The 
dosage of the product and the nature 
of control treatments may be adjusted 
so as to increase the chance that the 
study will demonstrate beneﬁ ts of the 
product or that adverse effects will 
not reach statistical signiﬁ cance. Also, 
unfavorable data may be deemed less 
relevant and may be left out of the 
abstract and the press release, or out 
of the paper itself. Finally, the whole 
publication may be cancelled or 
seriously delayed when the outcome 
is disappointing to the sponsor. 
Innocuous-sounding clauses in the 
contract may give the company such 
a veto right, and investigators may 
not fully realize the consequences of 
what they are signing. Some contract 
research organizations grant the 
sponsor that veto right up front. Even if 
researchers can legally publish the data, 
they may be reluctant to antagonize a 
major sponsor. 
There are indications that all these 
things happen [4,5], but there are few 
hard quantitative data to prove it. As 
Marion Nestle said in her landmark 
book [5]: “I could not ﬁ nd anyone 
who would speak to me ‘on the record’ 
for this book. When I told friends in 
government, food companies, and 
academia that I was writing a book 
about how the food industry affects 
nutrition and health, they offered to 
tell me anything I wanted to know, but 
not for attribution.” We obviously need 
more studies of the relations between 
industry and nutrition research, and 
they may need to go beyond the data 
made public in scientiﬁ c journals. 
Meanwhile, what should we do? 
My personal experience makes 
me reluctant to support a blanket 
condemnation of industry-supported 
research, because collaboration with 
industry has allowed me to discover 
things that I could not have found 
otherwise. We discovered the effects of 
trans fatty acids on heart disease risk 
[6] thanks to the expertise of Unilever, 
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and the cholesterol-raising factor in 
unﬁ ltered coffee [7] thanks to Nestlé. 
But researchers dealing with industry 
may be subjected to pressure, and 
they need help to resist such pressure. 
Most universities now have a code of 
conduct on relations with industry 
and conﬂ icts of interest, but when the 
negotiations come down to the wire, 
and money and jobs are at stake, then 
a code of conduct may not be enough 
to keep a researcher on the straight 
and narrow. The Royal Netherlands 
Academy of Sciences has put forth 
an innovative proposal on how to 
supervise relations between researchers 
and their sponsors [8]. For now, 
the Lesser et al. study raises serious 
concerns that some food industries may 
distort the scientiﬁ c record on diet and 
health. Such concerns affect nutrition 
science as a whole, if only because they 
threaten public conﬁ dence in nutrition 
research, and once that conﬁ dence 
is gone nutrition research becomes 
irrelevant. 
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